Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · EpitalonWeak / none
LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma.
Epitalon appears here not as the study's subject but as a chemical tool. This is cancer-biology research into drug resistance in natural killer/T-cell lymphoma, identifying the protein LCP2 as a driver of senescence-related chemoresistance. Late in the work, the researchers used Epitalon together with chaetocin as senolytic agents and reported that this combination partially cleared therapy-induced senescent cells and improved chemotherapy response in vivo. That is a narrow, mechanistic use of Epitalon in a disease model, not a study of Epitalon's own properties, dosing or safety, and the effect is attributed to the pair, not to Epitalon alone. These are preclinical findings in cell and animal models; human data are needed before any clinical conclusions can be drawn. For readers interested in Epitalon, the takeaway is limited: it functioned as a senolytic in one lymphoma model, which neither establishes benefit nor generalizes to the anti-aging uses discussed elsewhere.
Cell death & diseasen=—AnimalMay 28, 2026 - Study · DSIPWeak / none
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
This narrative review, published in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, surveys the mechanistic rationale for using therapeutic peptides — including BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, tesamorelin, sermorelin, semax, selank, and epitalon — in orthopaedic and musculoskeletal contexts. As a narrative review, it synthesises existing literature rather than generating new data; it carries no experimental controls, no patient cohort, and no statistical analysis of outcomes. Readers should weight it as an expert-curated overview, not as clinical evidence. The review's own authors acknowledge the central limitation plainly: preclinical findings are promising, but clinical trials are currently lacking. That candid admission matters. For most peptides covered — BPC-157, TB-500, ipamorelin, and epitalon in particular — the mechanistic picture is built almost entirely on rodent and in-vitro models. Tesamorelin is the notable exception, carrying FDA approval for HIV-associated lipodystrophy on the basis of Phase III RCT data, though that evidence does not transfer to orthopaedic applications. The review is useful as a...
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviewsn=——Jan 1, 2026 - Study · TirzepatideWeak / none
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
This narrative review from Frontiers in Aging maps nine therapeutic peptides across aging-related domains — metabolic function, telomere biology, tissue repair, neuroprotection, GH modulation, and sexual function. The authors drew on 20 primary sources selected from PubMed, Scopus, and regulatory databases through January 2026. The core finding is an evidence stratification most readers of this space already sense: FDA-approved agents (tirzepatide, bremelanotide) rest on large-scale registration-quality trial data, while investigational peptides — epitalon, BPC-157, TB-500, Semax, GHK-Cu, CJC-1295, ipamorelin — show mechanistically interesting but methodologically limited signals, predominantly from preclinical models or small, often non-replicated studies. The critical caveat is the design itself. Narrative reviews are synthesis without meta-analytic rigour; the 20-source selection pool is modest for a field this broad, and the review does not appear to have applied formal quality-grading criteria. Conclusions therefore reflect the authors' judgment rather than a systematic evidence synthesis. For readers tracking investigational peptides: the review adds conceptual framing...
Frontiers in agingn=——Jan 1, 2026 - Study · EpitalonWeak / none
Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.
This item is a published correction to the Biogerontology paper reporting that Epitalon increased telomere length in human cell lines. No abstract is provided, so its contents cannot be summarized and no findings can be attributed to it here — corrections typically amend specific errors (figures, data, author details) in the original article rather than changing its central conclusions, but that cannot be confirmed from the title alone. Its practical significance is as a pointer: anyone relying on the underlying Epitalon telomere study should read this correction alongside it to know what was revised. The original work was itself an in-vitro cell-line study, so the broader caveat stands — these are laboratory findings, and human data are needed before drawing conclusions about Epitalon's effects on aging in people.
Biogerontologyn=—In vitroNov 15, 2025 - Study · EpitalonWeak / none
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.
This in-vitro study reports that Epitalon extended telomere length in human cell lines in a dose-dependent way — in normal breast epithelial and fibroblast cells via upregulation of hTERT and telomerase, and in breast cancer cell lines largely through the alternative lengthening of telomeres (ALT) pathway. That mechanistic split is the study's most interesting claim, and it aligns with Epitalon's proposed role as a telomerase activator. But these are isolated cells in culture, not animals or people, so the results are mechanistic signals only and cannot speak to whether Epitalon influences aging or is safe in vivo. The cancer-cell finding also cuts two ways: telomere lengthening in malignant cells is not obviously desirable, a caution worth noting for a compound marketed for longevity. Note too that a published correction attaches to this paper and should be read with it. Preclinical result; human data are needed before any clinical conclusions can be drawn.
Biogerontologyn=—In vitroSep 4, 2025 - Study · EpitalonWeak / none
The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy.
An in-vitro study testing Epitalon's antioxidant effects in a cell model of diabetic retinopathy — human retinal pigment epithelial cells (ARPE-19) injured by high glucose. Researchers reported that high glucose slowed wound closure, raised reactive oxygen species, and pushed cells toward a fibrosis-associated transition, and that Epitalon countered these changes: restoring wound-healing behavior and dampening the fibrotic shift. The findings are mechanistically coherent with Epitalon's proposed antioxidant activity. But the limits are substantial, and the authors are candid about them — this is a single cell line in a dish, a simplified stand-in for a complex retinal disease, with no animal or human data, and the paper itself calls for more mechanistic work and notes that safety is unconfirmed. These are preclinical findings; human data are needed before clinical conclusions can be drawn. Interesting as an early signal of a possible eye-related application, and nothing more.
Stem cell reviews and reportsn=—In vitroAug 1, 2025 - Study · EpitalonWeak / none
Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties.
A narrative review synthesizing roughly 25 years of Epitalon research — the tetrapeptide AEDG, derived from a bovine pineal-gland extract. It usefully catalogs the reported effects (geroprotective, neuroendocrine, antioxidant, neuroprotective, antimutagenic) and candidate mechanisms, from telomerase activation to influence on melatonin synthesis and immune signaling, and candidly flags how much remains uncertain — including that the compound's physico-chemical and structural characterization is still thin. As a review it aggregates but does not weigh study quality, and the underlying literature is dominated by in-vitro and animal work, much of it from a single research lineage; human clinical evidence is limited. So while the breadth of reported activity is striking, it should be read as a map of hypotheses, not a verdict on efficacy or safety. These remain largely preclinical signals; controlled human data are needed before clinical conclusions can be drawn. A good orientation to what has been studied and what has not.
International journal of molecular sciencesn=——Mar 17, 2025 - Study · EpitalonWeak / none
Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development.
This is an animal/laboratory reproductive-biology study using Epitalon as a telomerase activator to improve bovine egg (oocyte) and embryo quality during in-vitro production. Researchers reported that telomerase sits in the nucleus of healthy egg-support cells but is depleted and mislocalized in degraded ones, and that adding Epitalon significantly improved egg maturation rates, blastocyst hatching and implantation potential, alongside better markers of cellular health (lower reactive oxygen species, improved mitochondrial signals). The mechanism — telomerase activation — is consistent with Epitalon's proposed profile. But scope is narrow: this is cattle embryology in a dish, an agricultural and assisted-reproduction context, not a model of human aging or fertility, and dosing specifics are limited to that system. These are preclinical findings; human data are needed before clinical conclusions can be drawn. For Epitalon's broader longevity narrative, this adds a mechanistic data point about telomerase, not evidence of benefit in people.
Life sciencesn=—AnimalFeb 1, 2025